Puma Aims To File Nerlynx In Third-line HER2-positive Breast Cancer By July

 
• By Sten Stovall
  
Carcinoma
Filings to be based on Positive top line results from Phase III NALA trial • Source: Shutterstock

More from Anticancer

More from Therapy Areas